Compare AlphaGEN vs Angiogenix
Customers evaluate the quality of AlphaGEN's products using the following success metrics.
Overview
AlphaGEN is based in Japan
The company are developing siRNA drugs targeting a control factor for HIF (hypoxia-inducible factor), which is one of the main factors involved in angiogenesis. The company have found that siRNA can promote angiogenesis by inducing expression of several angiogenic factors simultaneously by preventing breakdown of HIF inside the cell. It is therefore expected that delivery of siRNA to disease-affected sites can efficiently induce angiogenesis, leading to a in treatment for obstructive arteriosclerosis.
Angiogenix is 27 yrs old and is based in United States.
Angiogenix, Inc. is an early-stage biotechnology company developing products for peripheral and cardiac ischemia. The Company's ACCLAIM(tm product candidates are proprietary nitrates focused on replacing a significant share of existing generic nitrate products with worldwide sales of about $3 billion. The Company's Vasotrophin(r product candidate is a novel angiogenic growth factor that stimulates both angiogenesis and arteriogenesis to produce robust new blood vessels. Vasotrophin can be injected directly into peripheral tissue and used with proven catheter technologies for cardiovascular applications. Angiogenix is located in Burlingame, California.
Demo Video
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because AlphaGEN has not claimed their profile.
Work for AlphaGEN? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for AlphaGEN?
Claim your profile now.
Information not available because Angiogenix has not claimed their profile.
Work for Angiogenix? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Angiogenix?
Claim your profile now.